Neladenoson bialanate (BAY 1067197)
Sponsors
Bayer
Conditions
Pharmacology, Clinical
Phase 1
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
TerminatedNCT04320771
Start: 2017-11-02End: 2018-12-17Updated: 2020-03-26
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
TerminatedNCT04322253
Start: 2017-08-24End: 2018-12-17Updated: 2020-03-26